n CME : Your SA Journal of CPD - Feminine forever? : main topic

Volume 22, Issue 11
  • ISSN : 0256-2170



HT is the only proven therapy for the treatment of vasomotor symptoms of menopause. <br>Systemic or local HT prevents and treats urogenital atrophy. <br>HT prevents the early bone loss of menopause and associated fractures. <br>HT is associated with a lowered risk of colorectal cancer. <br>HT increases the risk of VTE and stroke. <br>HT should not be used for the prevention of CAD. <br>EPT is associated with an increased risk of invasive breast cancer after 5 years of therapy. <br>Progestogen is only added in the presence of a uterus in order to protect against endometrial cancer. <br>Use the lowest dose of HT for the shortest period of time.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error